clinical trial · NCT07782996
A Study to Investigate the Efficacy and Safety of GSK5784283 Compared With Placebo in Participants With Uncontrolled Asthma (PERSIST ASTHMA-2)
AsthmaGSK5784283PlaceboStandard of care
brief summary
The study aims to demonstrate the superiority of GSK5784283 compared to placebo in reducing the annualized rate of clinically meaningful asthma exacerbations.
started
Aug 27, 2026
primary completion
May 4, 2029
completion
Dec 28, 2029
last updated
Sep 28, 2026
official title
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of GSK5784283 (Felcorekibart) as an Add-On Therapy in Adults and Adolescents With Uncontrolled Asthma (PERSIST ASTHMA-2)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol